Business Context and Reporting Period
Company: Aytu BioScience, Inc. (Note: Input metadata lists "AYTU BIOPHARMA, INC", but the filing identifies the registrant as "AYTU BIOSCIENCE, INC.")
Filing Type: Form 8-K (Current Report)
Date of Report: March 19, 2020
Event: Entry into a Material Definitive Agreement for a registered direct offering of securities.
Key Financial Metrics and Transaction Details
This filing reports a capital raise transaction rather than periodic financial performance metrics (revenue, profit, cash flow). Key transaction figures include:
- Gross Proceeds: $20.0 million.
- Common Stock Issued: 12,539,197 shares at $1.595 per share.
- Warrants Issued: Warrants to purchase up to 12,539,197 shares at an exercise price of $1.47 per share.
- Warrant Term: One year from issuance; exercisable immediately.
- Placement Agent Fees: 7.5% of gross proceeds plus a 1.0% management fee, $90,000 in non-accountable expenses, and a $12,900 clearing fee.
- Placement Agent Warrants: 815,047 warrants issued to the agent with an exercise price of $1.9938 per share.
Material Changes Versus Prior Period
The filing does not provide comparative financial data (e.g., revenue or profit changes) against a prior period. The material change reported is the execution of the securities purchase agreement on March 19, 2020, which will increase the company's share count and cash position upon closing.
Guidance, Outlook, and Risks
Closing Conditions: The offering is expected to close on or about March 23, 2020, subject to satisfaction of customer closing conditions.
Use of Proceeds: The filing text does not specify the intended use of the $20.0 million in gross proceeds.
Risks/Contingencies: The transaction is contingent on the closing conditions being met. The filing incorporates by reference the full text of the Purchase Agreement and Warrants for complete terms.
Investor Verification Checklist
- Verify the final closing date of the offering (expected March 23, 2020) and confirmation of net proceeds after fees.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.
- Confirm the dilution impact of the 12,539,197 new shares and associated warrants on existing shareholders.
- Check subsequent filings for the actual use of the raised capital.